Effects of pravastatin on murine chronic graft-versus-host disease

Transplantation

Volumn 90, Issue 8, 2010, Pages 853-860

  Yoon, Hyoung Kyu ^a   Lim, Ji Young ^a   Kim, Tae Jung ^b   Cho, Chul Soo ^a   Min, Chang Ki ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Chemokines; Chronic GVHD; Pravastatin; Scleroderma

Indexed keywords

CD11B ANTIGEN; COLLAGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; PRAVASTATIN; RANTES; CHEMOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINOR HISTOCOMPATIBILITY ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALOPECIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DERMATITIS; DOWN REGULATION; DRUG EFFECT; EPITHELIUM CELL; FEMALE; GRAFT RECIPIENT; HISTOCOMPATIBILITY GENE; HISTOLOGY; IMMUNOMODULATION; INFLAMMATORY CELL; LUNG FIBROSIS; LUNG LAVAGE; MOUSE; NONHUMAN; ORGAN DONOR; PNEUMONIA; PRIORITY JOURNAL; PROTEIN SECRETION; RADIATION DOSE; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; ANIMAL; BAGG ALBINO MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; ISOGRAFT; MOUSE STRAIN; PATHOLOGY; SKIN TRANSPLANTATION;

ANIMALS; CHEMOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MINOR HISTOCOMPATIBILITY ANTIGENS; PRAVASTATIN; SKIN TRANSPLANTATION; TRANSPLANTATION, ISOGENEIC;

EID: 78349296702     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181f2c92b     Document Type: Article

References (42)

1. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation ofperipheral blood stem cells versus bone marrow inallogeneic recipients: Long-term follow-up of a randomized trial. Blood 2002; 100: 415.
2. ZeccaM, Prete A, Rondelli R, et al. Chronic graft-versus-host disease in children: Incidence, risk factors, and impact on outcome. Blood 2002; 100: 1192.
3. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse. Blood 2002; 100: 406.
4. Kim J, Kim HJ, Park K, et al. Costimulatory molecule-targeted immu-notherapy ofcutaneous graft-versus-host disease.Blood 2007; 110: 776.
5. McCormick LL, Zhang Y, Tootell E, et al. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-ver-sus-host disease: A model for human scleroderma. J Immunol 1999; 163: 5693.
6. Zhang Y, McCormick LL, Desai SR, et al. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: Cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002; 168: 3088.
7. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425.
8. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78.
9. Charles-Schoeman C, Khanna D, Furst DE, et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipopro-tein in patients with rheumatoid arthritis: A pilot study. J Rheumatol 2007; 34: 1459.
10. Zeiser R, Youssef S, Baker J, et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 2007; 110: 4588.
11. Anderson BE, McNiff JM, Jain D, et al. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: Requirements depend on target organ. Blood 2005; 105: 2227.
12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248.
13. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229.
14. TrojanowskaM,LeRoy EC, Eckes B,et al. Pathogenesisoffibrosis: Type 1 collagen and the skin. J Mol Med 1998; 76: 266.
15. Pines M, Snyder D, Yarkoni S, et al. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 2003; 9: 417.
16. Gerbitz A, Ewing P, Olkiewicz K, et al. A role for CD54 (intercellular adhesion molecule-1) in leukocyte recruitment to the lung during the development of experimental idiopathic pneumonia syndrome. Transplantation 2005; 79: 536.
17. Hamilton BL. L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J Immunol 1987; 139: 2511.
18. Kraling BM, Maul GG, Jimenez SA. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995; 63: 48.
19. Campbell MJ, Esserman LJ, Zhou Y,etal. Breast cancer growth prevention by statins. Cancer Res 2006; 66: 8707.
20. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
21. Hamadani M, Awan FT, Devine SM. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood2008; 111: 3901.
22. Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006; 61: 729.
23. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945.
24. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001; 97: 1196.
25. + T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2007; 127: 1905.
26. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412.
27. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343: 1020.
28. Rollins BJ. Chemokines. Blood 1997; 90: 909.
29. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392:565.
30. Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol 2003; 15: 772.
31. Zhou L, Askew D, Wu C, et al. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2007; 127: 281.
32. + regulatory T cells. Blood 2007; 110: 3793.
33. + T cells that survive irradiation regulate chronic graft-versus-host disease. Blood 2004; 104: 1565.
34. Clark JG, Madtes DK, Hackman RC, et al. Lung injury induced by alloreactive Th1 cells is characterized by host-derived mononuclear cell inflammation and activation of alveolar macrophages. J Immunol 1998; 161: 1913.
35. Hildebrandt GC, Duffner UA, Olkiewicz KM, et al. A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 2004; 103: 2417.
36. Sauty A, Dziejman M, Taha RA, et al. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 1999; 162: 3549.
37. Ohmori Y, Schreiber RD, Hamilton TA. Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J Biol Chem 1997; 272: 14899.
38. Czermak BJ, Sarma V, Bless NM, et al. In vitro and in vivo dependency of chemokine generation on C5a and TNFalpha. J Immunol 1999; 162: 2321.
39. Marfaing-Koka A, Devergne O, Gorgone G, et al. Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNFalpha and inhibition by IL-4 and IL-13. J Immunol 1995; 154: 1870.
40. Panoskaltsis-Mortari A, Strieter RM, Hermanson JR, et al. Induction of monocyte- and T-cell-attracting chemokines in the lung during the generation of idiopathic pneumonia syndrome following allogeneic murine bone marrow transplantation. Blood 2000; 96: 834.
41. Hori A, Kanda Y, Goyama S, et al. A prospective trial to evaluate the safety and efficacy of pravastatin for the treatment of refractory chronic graft-versus-host disease. Transplantation 2005; 79: 372.
42. Mason RP, Walter MF, Day CA, et al. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005; 96: 11F.